Background: Chondrosarcoma (CS) is a rare malignant cartilage forming tumor accounting for 6% of skull base neoplasia. CS often presents insidiously, it almost never metastasizes but it has an indolent progressive course leading to significant morbidity and mortality due to invasion of the clivus and central skull base. This study performed a review of the management of CS.
Introduction
Chondrosarcoma (CS) is a rare malignant cartilage forming tumour (1) . CS mostly commonly occur in isolation but they can develop in non-hereditary skeletal disorders characterized by multiple enchondromas (Ollier disease and Maffucci syndrome), and these conditions are associated with IDH1 and IDH2 mutations (2) (3) (4) (5) . Previous irradiation and previous intravenous thorium dioxide contrast use has been described as a possible cause of these tumours. Other reported associations include malignant conditions such as osteosarcoma, malignant melanoma, fibrosarcoma and leukaemia as well as benign pathologies including fibrous dysplasia and Paget's disease (6, 7) . The differentiation of chordomas from CS can be difficult and relies on clinical, radiological and histological features (8, 9) . The clinical features of chordoma and chondrosarcoma are similar; headache and diplopia (abducens nerve palsy) are common in both groups (10, 11) . Multiple cranial nerve palsies are more common in patients with chondrosarcoma, reflecting the tendency of chordomas to originate in the clivus whereas chondrosarcomas are more likely to originate in the petroclival synchondrosis (junction of clivus and petrous bone) or sinonasal region.
Radiological imaging can help differentiate chordoma and chondrosarcoma based on location. Calcifications are more common with chondrosarcomas with characteristic ring-forming calcifications with computed tomography (CT) (12) . Both tumour types are heterogenously bright on T2-weighted magnetic resonance imaging (MRI). It is possible that diffusion weighted MRI may make imaging even more reliable in the future (13) (14) (15) .
The morphology of chordoma is highly variable but three fea- were used to differentiate chondrosarcoma from chordoma.
CS is cytokeratin and EMA negative but chondroid chordoma is cytokeratin and EMA positive (16) (Table 1) . Oakley et al. (17) , using a microarray approach, reported that podoplanin, (D2-40 antibody), could be a useful positive marker for CS. The accuracy of podoplanin is however less than previously reported, and the staining pattern can be somewhat difficult to interpret. Although further studies have indicated that low grade chondrosarcomas are S100 positive in virtually 100% of cases, chordoma is positive in well over 90% of cases. Similarly SOX-9 is positive in both chondrosarcomas and chordomas. On the other hand, brachyury (a transcription factor essential for notochordal cell differentiation) appears to be negative in the vast majority of chondrosarcoma but positive in most chordomas (17, 18) .
Thus, a panel of cytokeratin (pancytokeratin or AE1/AE3), EMA, brachyury and D2-40 is currently the gold standard. Recently detection of a variety of genetic differences have been used to characterise CS more thoroughly, e.g. detection of mutations by direct sequencing of isocitrate dehydrogenases 1 and 2 (IDH1/2) (19, 20) .
CS account for 10-20% of all malignant bone tumours most commonly arising in the long bones and pelvis (2, 21, 22) . In about 3% to 10% of cases it has been reported that CS has arisen in the head and neck region (2, 12, 23) accounting for 6% of skull base tumours in total (24) . CS were classified into primary, secondary and mesenchymal by Myers and Thawley in 1979 (25) . Mesenchymal CS arise from primitive mesenchymal cells whereas secondary CS arise from pre-existing cartilaginous lesions such as chondroma or exostosis. Mesenchymal CS is considered a distinct clinical entity compared to CS as it has a more aggressive clinical course (26) and as such it is not discussed any further in this review. Primary CS can occur within cartilaginous structures or bones that ossified from cartilage but curiously they can also arise within soft tissue. These lesions are thought to arise from ectopic chondroid precursor cells or from cartilaginous differentiation of primitive mesenchymal cells that have failed to be resorbed during development (12, 22) and this potential origin may help to explain the multifocal nature of the disease. Further attempts have been made to grade CS based on histological appearance (5) .
The World Health Organization (WHO) classification recognizes 3 grades, based upon nuclear size, staining pattern (hyperchromasia), mitotic activity, and degree of cellularity (27) . WHO Grade I is well differentiated and low grade. The cellularity is higher than with enchondroma but with occasional plump nuclei. The classic histological subtype falls into this category and is the most common type seen in the skull base (approximately 90%), and in more elderly patients (60-70 years This is seen more in younger patients (20-40 years) and has a higher tendency for recurrence (28) .
In keeping with other sinonasal malignancies, CS often present insidiously with nasal obstruction, epistaxis or facial pain and if there is skull base involvement, various cranial nerves can also be affected. Anatomical sites commonly involved include the ethmoid and the maxillary sinuses, the nasal septum (either superior or inferior to invade anterior skull base or hard palate All patients were treated surgically for primary tumour and any recurrence combined with conventional radiotherapy (RT) in a small number of cases. and the vast majority of these patients (greater than 80%) were treated with adjuvant proton beam therapy (5, 32) . Surgery alone accounted for 30.4% of patients. These 2 treatment strategies accounted for almost all the patients (94.4%), however there were a variety of less often used therapies which are illustrated in Table 3 . Trying to establish a combined outcome measure or subset survival analysis of these heterogeneous studies has proven impossible, mostly because they have used different outcome reporting measures with various follow up times, and different treatment modalities. Information for example on gross total resection was often lacking. Despite this, the majority of studies (15/18, Lund VJ, (4, 29, (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) ) did include individual patient status and it is certainly possible to conclude that the majority of patients recorded were either alive and well (AEW, 156/229 (68.1%)) or alive with disease (AWD, 38/229 (16.6%)) with only 15.3% (35/229) reported as dead of disease. The range of followup for this data was 3 months to 39 years but it is not possible to determine any standardized survival metrics.
Results
Those few studies with long term follow-up (4, 23, 34, 37, 41, 42, 47) show respectively), the petro-clival area and clivus. However, the disease can also be multifocal (2, 7, 23, 29, 30) . Low grade CS almost never metastasise but they do have an indolent and progressive course leading eventually to significant morbidity and mortality.
The initial aim of this study was to perform a meta-analysis of the management of CS of the skull base and sinonasal areas.
However, it became clear during the literature review that there had been no previous meta-analysis on this topic and only one systematic review was identified (31) . This was because there
were no large series with standardized treatments and follow 
Materials and methods

Review of the literature
A review of the English language literature using the search string "chondrosarcoma AND (skull base OR sinonasal OR nasal OR nose OR sinus) NOT mesenchymal" was undertaken using the Cochrane review, Embase and Pubmed databases.
555 articles were initially identified, the titles and abstracts were examined with studies excluded if they did not pertain to CS. More than 50 single patient case reports were identified but they were excluded and only studies with greater than 3 patients were included. Finally only studies with survival data that included lesions within the mandible, maxilla, sinonasal region or skull base were included in the final analysis. Studies that also included lesions elsewhere in the head & neck region or included mesenchymal CS were included as long as data on the sinonasal non-mesenchymal cases could be extracted. This left 20 studies that are described in Table 2 . One further study has been added to Table 2 that includes the data from two of the senior authors (VJL & DH). The evidence presented in Table 2 is comprised, at best, from pooled analysis of small to mediumsized case series. The data is heterogeneous and the quality of the data, in terms of treatment and outcomes is often poor.
There are no randomised controlled trials nor any prospective trials of any nature reported in the literature. Thus meta-analysis was not possible and it is extremely difficult to arrive at any firm conclusions.
Single centre data
All patients treated at The Royal National Throat Nose and Ear
Hospital, London, UK for low grade sinonasal CS over a 37 year period, from 1980 to 2017, were included in the study. Data was collected prospectively by the authors (VJL & DH) along with long-term follow up. All cases were examined by an expert pathologist in sinonasal tumours confirming the histological diag- (1) AWD (9), AEW (38), follow up 0.9-23.5yrs
Kiratli et al (39) Not stated 43-75yrs; 1:2 Retrospective study; maxillary sinus (1), sphenoid (1), ethmoid
3; Grade 1 (2), Grade 3 (1)
Vaz-Guimaraes et al (46) 2004 Lee et al (40) 1990-2002 26-56yrs; 3:1 Retrospective study; ethmoid (2), maxillary sinus (1), skull base (1) 4; Grade 1 (1), Grade 2 (2), Grade 3 (1)
AEW (range 2.5 -14.25yrs)
Prado et al (41) 1953-2002 11-70yrs; 9:7 Retrospective study; maxilla ( Gadwal et al (29) 1970-1997 3-18yrs; 8:6 Retrospective study; maxillary sinus (4), mandible (3), nasal cavity (2), nasopharynx (1), orbit (1), skull base (1) 14; Grade 1 (9), Grade 2 (1), Grade 3 (4)
Sx (7), Sx+RT (7) AEW (11), AWD (1), no follow data (3)
Rosenberg et al (5) 1978 Coates et al (36) 1952-1977 Not stated; 6:7 Retrospective study 13; not stated Local excision (7), CFR (6)
Local excision LR (5), CFR AEW (4) DOD (2)
Fu et al (38) Not stated 20months-69yrs; 6:4
Retrospective study; involving nasal cavity/ paranasal sinuses/ nasopharynx 10; Grade 1 (6), Grade 2 (3), Grade 3 (1) Sx (9), biopsy only (1) AEW (6), follow up 2yrs, 3yrs, 3yrs, 6yrs, 11yrs, 13yrs; DOD (4), 0.5yr, 1yr, 1.5yrs, 4yrs
Key: Sx + RT = surgery then radiotherapy; CRT = chemoradiotherapy; RT = radiotherapy alone; CFR = craniofacial resection; AEW = alive and well; AWD = alive with disease; LR = local recurrence; DOD = dead of disease; CFR + RT = craniofacial resection then radiotherapy; CFR + C = craniofacial resection then chemotherapy; C = chemotherapy alone; OS = overall survival; DFS = disease free survival; DOAC = dead of another cause; ES = endoscopic surgery.
that the majority of cases develop recurrence either close to the site of origin or elsewhere in the anatomical area which can occur many years later. These have been treated surgically, in some cases multiple times but with increasing inaccessibility particularly in the middle cranial fossa, which may ultimately result in the patient's death. Thus whilst 5 year survival rate of 94% was found after craniofacial resection in a cohort of 24 patients, at 15 years this has fallen to 37% (48) .
Discussion
Treatment strategies
Although the literature is entirely comprised of retrospective case series, it is clear that surgery has been the primary treatment in almost all cases. Formal craniofacial resection provided the gold standard approach from the 1980's onwards; however, more recently ES has been employed where applicable.
Extensive disease extending beyond the dura, or laterally into the orbits is less amenable to an ES approach, but in those cases where the principles of oncologic resection can be preserved, ES is an acceptable approach for the resection of sinonasal CS.
Unfortunately there are no studies directly comparing different surgical strategies in CS. An unresolved question is whether complete surgical resection or maximum safe resection should be the aim when several authors have reported excellent local control (LC) and overall survival (OS) rates with only partial resection followed by post-operative proton beam therapy (5, 32, 49) .
Surgery
The vast majority of included studies used surgery as the There is growing evidence that in selected cases ES is a good approach for the clearance of CS (50, 51) and that it has been found to be both safe and effective (52) . There have been several studies reporting in a small number of patients that ES is an acceptable approach for clearance of CS (53) (54) (55) (56) (57) . Moussazadeh et al (58) reported on 8 patients treated with ES. They achieved greater than 95% resection of the tumours in 5 out of 8 of their patients with only one cerebrospinal fluid leak as a complication and partial improvement in existing cranial neuropathies. However, there was no long-term data on survival in this study. Folbe et al (59) argue that ES has become the standard of care for many clival lesions although other techniques maybe necessary if the lesions are very extensive or extend laterally. Messerer et al (60) reported that the ES approach allows excellent access to midline clival lesions and can be combined with an open approach to achieve excellent tumour clearance.
Chemotherapy and radiotherapy
Chemotherapy does not play any role in the treatment of CS Radiotherapy however, significantly improves local control when it accompanies surgery (61) . between proton beam therapy, conventional therapy or ion therapy studies (62) .
Conventional RT, however, has been found by various investigators to be effective as an adjunct therapy. Sahgal et al (63) reported on 18 patients treated with surgery initially (biopsy or partial resection) followed by intensity modulated RT (IMRT) at 70 Gy (2Gy/fraction). They reported a 5-yr OS of 87.8% and LC rates of 88.1%. Interestingly, they reported that the predictors for LC were gross total surgical resection and age. Potluri et al (49) reported that surgical resection is essential but that adjunct high dose photon therapy can keep small volume disease under control. Gwak et al (64) reported that stereotactic radiation technique using the Cyberknife system with hypofractionated doses was an effective treatment in these tumours. Gamma knife radiosurgery has also been reported as a useful adjunct strategy after surgery (65) . Martin et al (66) reported actuarial LC for chondrosarcomas at 5 years was 80 ± 10.1% after post-operative gamma knife radiosurgery. In addition, Kano et al (67) reported on 46 patients treated for CS, 36 of which had prior surgical treatment. The actuarial OS after stereotactic radiosurgery was 89% at 3 years, 86% at 5 years, and 76% at 10 years.
Proton beam radiotherapy has several advantages over conventional photon beam radiotherapy, chief amongst which is the ability to limit damage to normal tissues surrounding the target lesion better. Sparing of normal tissue allows delivery of higher doses that increase chances for effective eradication of vital tumour cells. This is of crucial importance when treating residual disease located in close proximity to vital structures at the skull base (68) . Demizu et al (69) treated 72 patients with sarcomas of the skull base (the majority) or spine of which 20 were CS; the 5-year OS, progression-free survival, and LC rates were 75.3%, 49.6%, and 71.1%, respectively. They concluded that proton beam treatment was a safe and effective treatment. Weber et al (70) reported the largest single institution series of patients treated with only proton beam radiotherapy (77 patients). They reported the actuarial 8 year LC and OS were 89.7% and 93.5%, respectively, with high-grade radiation-induced toxicity observed in 6 patients. Similar to other studies they reported that protons were both safe and effective. Feuvret et al (32) reported on 159 patients treated initially with surgery and then either protons alone or combination of protons and photons. They concluded that although maximal safe surgery forms the mainstay of treat- ment, post-operative proton treatment offered high rates of LC with low toxicity. The authors described OS rates of 94.9% and 87% at 5 and 10 years, respectively. Similarly Rosenberg et al (5) reported LC rates at 5 and 10 years of 99% and 98%, respectively, and OS of 99% at 5 and 10 years when treating 200 CS with surgery then proton beam therapy; similar results have been reported by others (71) . Encouragingly, Srivastava et al (72) report that proton beam therapy does not have a significant impact on health-related quality of life parameters.
Several authors have reported that carbon ions are also a safe and effective treatment for CS (73, 74) . In addition to spatial superiority in distribution of radiation dose when compared to conventional photon techniques, the carbon ions also have a higher biological impact in irradiated tissues then either protons or photons. Uhl et al (74) reported that carbon ion therapy in 
Outcomes
Jones et al (76) performed a study using data from the USA (34) have also demonstrated that higher tumour stage, larger categorical size (<4cm versus ≥4 cm), lack of adjuvant radiation, and longer duration of follow-up were associated with greater risk of recurrence. Several other authors have also separately reported that gross tumour volume and age were negative prognostic indicators (70, 71) .
Around 90% of all lesions are altogether WHO Grades I and II (77) . The predominance of the low-grade types within the skull base gives this condition its overall good prognosis. Grade III tumours are rare in the skull base and are associated with a worse prognosis (78) .
Bloch et al (79) and 87%, respectively (5, 32) .
There is no consensus on how to treat recurrent disease. Some authors choose to treat with proton beam treatment (5, 32) whereas others have opted for surgery (48, 55) . The majority of included studies used a combination of approaches and certainly further work is needed to clarify the situation. It is likely that surgery if feasible would offer the best chance of cure and the form that this surgery took would be dictated by the extent and location of the disease, whilst proton beam treatment is useful for disease that is inaccessible or in high risk anatomical areas such as the optic chiasm. Indeed CS is one of only a few sinonasal tumours that can affect both optic nerves and/or chiasm leading to blindness. Judgement of operability is subjective, however, and depends greatly on the experience of the surgical team.
Although there is a lack of high level evidence available for the treatment of this condition, we have suggested a treatment protocol based partly on the authors' experience and partly on the European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base (81) which is illustrated in Figure 1 . This algorithm advocates lifelong followup as recurrence in CS can occur in distinct separate, previously uninvolved, anatomical areas of the skull base many years after initial treatment (48, 55) .
Future treatments
Huang et al (82) have suggested a mechanism for chemoresistance of CS which they report is due in part to overexpression 
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